On the basis of results of the most recent CVOTs (DAPA-HF, DAPA-CKD, EMPEROR-R), the FDA has approved dapagliflozin (2020) and empagliflozin (2021) to reduce risk for CV death and HF hospitalization in adults with HF and reduced ejection fraction regardless of whether they have diabetes [24, 25]
The Wegovy SmPC notes that while gastric emptying is delayed, clinically relevant interactions with most oral medicines are not expected
[1] [2] Outcomes are generally good
"It should therefore only be offered following assessment of the person taking the medication and as part of a programme to establish a healthy lifestyle." Charity Beat raised concerns about the impact of the drug on people with eating disorders
You will be required to complete a short consultation when ordering this product
For patients wanting jawline contouring or help with a double chin, FaceTite and Laser Lift shrink unwanted fat while tightening skin for a smoother profile